PROGRAM

 

 Thursday, 29 November 2018

  13:30Registration
  15:00Opening remarks
Charles Boucher
Erasmus Medical Center, The Netherlands
 Session 1: Respiratory viruses: Global trends and current challenges
Chairs: Kirsty Short &  Matthias Götte
  15:15Keynote lecture: Current challenges, regulatory considerations, and emerging viruses
Ralph Baric
University of North Carolina, USA
  15:45Plenary Lecture: Opportunities and Challenges for a Broadly Protective Influenza Vaccine
Gary Nabel
Sanofi, USA
  16:05BREAK 
   
 Session 2: Therapeutics against respiratory viruses: Clinical advances &
industry perspective (Non-CME session)
Chairs: Raymond Schinazi & Gary Nabel
  16:25Baloxavir is a first-in-class oral cap-dependent endonuclease inhibitor for treatment of influenza: overview of pre-clinical, phase I and II trials
Takeki Uehara
Shionogi, Japan
  16:45Baloxavir is effective and well tolerated in treating otherwise-healthy and high-risk influenza patients: overview of phase III trials
Andrew Ackrill
Roche, UK
  17:05RV521: A new and potent RSV fusion inhibitor in clinical development
Stuart Cockerill
ReViral, UK
  17:25Cocrystal Pharma: Influenza drug pipeline design
Sam Lee
CoCrystal Pharma, USA
  17:45Discovery and development of novel and potent non-fusion inhibitors of RSV 
Michael Rodin
Enanta Pharmaceuticals, USA
  18:05End of Day 1
  19:00Conference Dinner
   
 

 Friday, 30 November 2018

 Session 3: Basic science, enzymology and respiratory virus inhibition strategies
Chairs: Masaru Kanekiyo & Charles Boucher 
  9:00State-of-the-art lecture: Enzymology of RSV and influenza RdRp  
Matthias Götte               
University of Alberta, Canada
  9:30Difficulties and barriers in developing RSV polymerase inhibitors
Rachel Fearns
Boston University School of Medicine, USA
  9:50Respiratory Syncytial Virus Binds to a Signaling Coreceptor which Induces Recruitment of its Receptor, Nucleolin, to the Cell Surface during Entry 
David Marchant
University of Alberta, Canada
  10:10BREAK 
   
 Session 4: New study models and complications beyond acute respiratory infection
Chairs: David Marchant & Rachel Fearns
  10:40State-of-the-art lecture: Respiratory tract infections and chronic conditions: The case for influenza and diabetes
Kirsty Short
University of Queensland, Australia & Erasmus MC, the Netherlands
  11:103D Human epithelial models to study respiratory virus pathogenesis
Samuel Constant
Epithelix, Switzerland
  Oral Abstract Session 1
  11:30SB 9200 is a novel broad-spectrum antiviral agent effective against both RSV and Flu (#101)
Diane Schmidt                                
Spring Bank Pharmaceuticals, USA
  11:40Structure-based prediction of influenza resistance mutations (#102)
Bryan Cox
Emory University, USA
  11:50Risk factors for RSV severity in immunocompetent and immunocompromised adults presenting in an emergency department (#103)
Slim Fourati                         
Inserm, France
  12:00Evaluation of the therapeutic potential of antibody and T cell targeted immune responses towards RSV small hydrophobic protein (#105)
Genevieve Weir                          
IMV, Inc., Canada
  12:10Panel Discussion
  12:25Lunch & Free Afternoon
  15:15Poster Reception 
   
 Session 5: Immunology and advances in vaccine development
Chairs: Ralph Baric & Asuncion Mejias
  16:00Plenary Lecture: Respiratory syncytial virus pathogenesis & special pediatric populations
Asuncion Mejias
The Research Institute At Nationwide Children’s Hospital, USA
  16:30Nanoparticle display of influenza antigens for development of a universal influenza vaccine
Masaru Kanekiyo
NIH, USA
  16:50Advances in vaccine development against Respiratory Syncytial Virus
Martin Moore
Meissa Vaccines, USA
  Oral Abstract Session 2
  17:10Non-targeted diagnosis of multiple viral infections by means of shotgun metagenomic using deep sequencing  (#104)
Slim Fourati                   
Inserm, France
  17:20mRNA vaccines expressing forms of RSV-F protein are immunogenic and protective in preclinical models of respiratory syncytial virus infection (#106)
Amy Espeseth                                
Merck, USA
  17:30Panel Discussion
  17:45Concluding remarks
Raymond Schinazi
Emory University, USA
  18:00End of Workshop